Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Dermatologic 2Tumor-Agnostic 1Other neoplasm 1Lymphoid 1

Conditions

Precancerous Conditions 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Keratosis, Actinic 1Dermatitis, Contact 1Carcinoma, Basal Cell 1

Interventions

Ipilimumab 123pembrolizumab 101Nivolumab 100aldesleukin 89Cyclophosphamide 85fludarabine phosphate 64Interleukin-2 58Dacarbazine 573-ingenyl angelate 42Vemurafenib 39Temozolomide 39Imiquimod 39trametinib 37sargramostim 37Peripheral Blood Stem Cell Transplantation 36incomplete Freund's adjuvant 35dabrafenib 32fludarabine 31Radiotherapy 31Aminolevulinic Acid 30Bevacizumab 29Carboplatin 28Whole-Body Irradiation 25Photochemotherapy 25Paclitaxel 25Filgrastim 25Biopsy 25Interferon-alpha 24Cisplatin 23Sorafenib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Triamcinolone × Dermatologic × Clear all
NCT03380026 2021-11-24

MIDAS

Rochester Skin Lymphoma Medical Group, PLLC

Phase 2 Completed
28 enrolled 8 charts
DermatologicLymphoid

Dermatitis, Contact, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT00021294 2018-09-11

Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis

University of Arizona

Phase 2 Completed
DermatologicOther neoplasm

Carcinoma, Basal Cell, Precancerous Conditions, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡